SA
RXRX icon

Scarborough Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Scarborough Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,790
Closed -$5.5K – 569
2026
Q1 		$5.5K Hold
1,790
– – ﹤0.01% 515
2025
Q4 		$7.32K Buy
1,790
+280
+19% +$1.39K ﹤0.01% 284
2025
Q3 		$7.37K Hold
1,510
– – ﹤0.01% 275
2025
Q2 		$7.64K Buy
+1,510
New +$7.42K ﹤0.01% 260

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Scarborough Advisors's RXRX Position: Q2 2026 in Review

Scarborough Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 1,790 shares — an estimated $5.5K sold.

Scarborough Advisors first reported a position in RXRX in Q2 2025 and held it in 4 quarters. The position peaked at $7.64K in Q2 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Scarborough Advisors reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 1,790 Recursion Pharmaceuticals shares in Q2 2026, an estimated $5.5K.
  • Scarborough Advisors first reported a position in Recursion Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Scarborough Advisors's Recursion Pharmaceuticals position peaked at $7.64K in Q2 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.